Solventum Corporation (SOLV) Business Profile

What it does

Solventum is a global healthcare company that develops, makes and sells medical products, dental and orthodontic products, and healthcare software. Its offerings are used across prevention, diagnosis, treatment and recovery, including in hospitals, clinics, dental practices and other care settings.

MedSurg sells wound-care systems and dressings, skin-care products, synthetic tissue matrices, I.V. site-management products, sterilization-assurance products, temperature-management products, surgical supplies, medical tapes and wraps, stethoscopes, electrodes, and medical-technology components for other equipment makers. These products are intended to help clinicians treat wounds, prevent infection and complications, and manage procedures.

Dental Solutions sells products used throughout dental care, including brackets, aligners, restorative cements and bonding agents. Health Information Systems sells software for clinical documentation, billing and coding automation, speech recognition, classification and data visualization. Its software is designed to reduce administrative work and support reimbursement accuracy.

The company has approximately 20,000 employees, including approximately 2,000 in research and development. Its R&D work combines research scientists, engineers, data scientists, software engineers and product developers across its businesses.

How it makes money

Solventum earns revenue by selling consumable medical and dental products, capital-related clinical products and equipment, and software and rental offerings. Its three operating segments are MedSurg, Dental Solutions and Health Information Systems. MedSurg accounted for 57.9% of 2025 total sales, Dental Solutions for 16.2%, and Health Information Systems for 16.3%.

MedSurg is the largest business. Its wound dressings, I.V. site-management products, sterilization products, surgical supplies and other clinical consumables are used in care delivery and can generate repeat purchasing as providers replenish products. The business also includes negative-pressure wound therapy and medical-technology OEM products. Dental Solutions sells restorative, preventive and orthodontic products, including brackets and aligners. Health Information Systems generates software and rental revenue from documentation, revenue-cycle, coding, speech-recognition and analytics tools; its costs include installation, training and maintenance compensation, software licenses, and the maintenance and refurbishment of rental hardware.

Product pricing can be constrained by government reimbursement, price-control laws and healthcare cost-containment measures in some markets. The company manages sales through direct sales, distributors, key-account management, inside sales and e-commerce.

In Q2 2026, sales were $2.2 billion, including approximately $125.0 million of ERP-related advanced orders that the company expects to mostly reverse in Q3. In 2025, its Health Information Systems growth reflected expanded adoption of its 360 Encompass and performance-management solutions.

Customers and how it sells

Solventum serves a varied healthcare customer base, from multidisciplinary hospitals to local clinics and practices. Its products are principally purchased by hospitals, physicians and other healthcare providers, which commonly seek reimbursement from government programs and private insurers for the care they provide. Dental customers use its restorative, preventive and orthodontic products, while healthcare systems use its software to support documentation, coding, billing and workflow.

The company sells in more than 90 countries. It uses direct-to-customer sales, distribution, key-account management, inside sales and e-commerce, supported by marketing and service teams. Its clinical specialists, medical liaisons and application engineers provide clinical or technical customer support.

In Latin America, Europe, the Middle East and Africa, and Asia, the company also uses an export model and local third-party partners. These partners support regulatory and import compliance and distribute products to customers, while Solventum provides technical, clinical and marketing support. The company reports sales by the location where customers take possession of products or where services are rendered.

Suppliers and costs

Solventum runs sourcing, production and distribution globally. Its manufacturing network is supported by advanced manufacturing and assembly capabilities and a hub-and-spoke distribution model. The company says its supply-chain resilience program uses regional sources of supply, dual-source manufacturing and vertically integrated operations.

It continues to use certain 3M distribution networks and manufacturing sites under transition agreements while building independent capabilities. Product costs include manufacturing, engineering and logistics. In 2025, product costs as a percentage of product sales increased because of approximately $55 million of tariffs, the full-year impact of products sourced under 3M supply agreements, and higher logistics costs, partly offset by savings programs.

The company generally buys materials and services as needed and says it has no unconditional commitments for most purchases. It had approximately $330 million of unconditional purchase obligations over the next five years at December 31, 2025, primarily for IT-related obligations.

Competitive position

Solventum operates in competitive global markets. In advanced wound care, its principal competitors include Smith & Nephew, Medaxis, Mölnlycke, Coloplast and Convatec. In infection prevention and surgical supplies, named competitors include Becton Dickinson, Hartmann, ICU Medical, Medline, Cardinal Health, Fortive, Steris, MDF Instruments and BSN.

In dental and orthodontics, Dentsply Sirona, Envista and Straumann compete in both dental and orthodontic solutions; Ivoclar competes in dental products and Align Technology in orthodontics. In healthcare software, named competitors include Optum, Microsoft (Nuance), Epic, Oracle (Cerner), Waystar and Athena, alongside start-ups in revenue-cycle management and clinician productivity.

The company says its competitive position depends on delivering differentiated clinical and economic outcomes. It protects technologies with patents, designs, trademarks, copyrights, trade secrets, regulatory exclusivity and confidentiality agreements. It also cites customer relationships, technology expertise and manufacturing know-how.

Our reading: Customer relationships, clinical support and a broad installed product portfolio are meaningful competitive supports because they link Solventum to hospitals and care workflows, but customers have many named alternatives across every segment. (item1)

Our reading: Intellectual property and manufacturing know-how support differentiation, although the company does not identify any single IP asset or group as material to the business. (item1)

Growth opportunities

The company identifies aging populations, chronic conditions, demand for workflow efficiency, digital and data-driven care, care shifting to lower-cost settings, and personalized care as healthcare-market drivers. It is concentrating commercial and innovation resources on five growth drivers, including I.V. site management, negative-pressure wound therapy, sterilization assurance, dental restorative products and revenue-cycle management.

In MedSurg, the company is expanding Tegaderm CHG and recently launched V.A.C. Peel and Place dressing and sterilization products. It says Tegaderm CHG is the only transparent dressing cleared by the FDA to reduce catheter-related bloodstream infections, and that studies show nearly 60% lower infection rates than non-CHG solutions. In Dental Solutions, it is developing restorative and aesthetics products. In Health Information Systems, it is developing AI-driven autonomous coding and pursuing international expansion.

The company acquired Acera in 2025. In Q2 2026, Acera contributed $32 million to reported sales and grew 48%, driven by synthetic tissue-matrix technology. The company expects to launch almost 20 products through Q1 2028, including advanced-wound-care launches in the first half of 2027.

The company is advancing a separation of Health Information Systems, through either an independent company or combination with a scale participant. It expects to maintain investment and execute the innovation roadmap during the process. The company also expects its Q2 ERP advanced-order benefit to mostly reverse in Q3.

Structural risks

• Separation and debt: Solventum’s historical pre-separation financial information may not represent the results it would have achieved as a standalone public company. Debt incurred in the separation can reduce cash available for investment, strategic transactions and capital returns, and can limit financing flexibility.

• 3M transition execution: The company is still exiting transition service agreements and moving systems and supply-chain activities from 3M. Delays, higher transition costs, manufacturing relocations or disruption of supply arrangements could affect operations and cash flow.

• Regulatory and quality requirements: Medical-device and pharmaceutical products require regulatory compliance across development, manufacturing, labeling, promotion and post-market surveillance. Clearances and approvals can be rigorous, costly and time-consuming, and may limit product uses or be delayed.

• Healthcare pricing and reimbursement: Cost-containment initiatives, reimbursement changes, price controls and healthcare-delivery reforms can limit prices or reimbursement and affect whether providers select the company’s products.

• Competition and technology change: Competitive markets, new technologies and entrants can require price reductions or lead to lost share. Healthcare software is specifically described as dynamic, with continued product and technology introductions.

• Global operating exposure: Tariffs, international trade conditions, foreign exchange, environmental requirements, data-privacy rules and geopolitical conditions can raise costs, restrict supply or create compliance obligations.

Bottom line

Our reading

Our reading: Solventum is a healthcare operating business built mainly around MedSurg consumables and equipment, alongside dental products and healthcare software; its sales model reaches providers globally through direct and distribution channels. (item1)

Our reading: The company is completing its operational separation from 3M while reshaping the portfolio through the Health Information Systems separation and Acera integration, making execution, transition costs and debt service central considerations. (item1a; call_prepared)

Our reading: Its product-development program and installed customer relationships provide routes to expand adoption, but the company competes with established suppliers and software providers in each segment. (item1; call_prepared)